Compare VLN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | BDTX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.2M | 220.3M |
| IPO Year | N/A | 2020 |
| Metric | VLN | BDTX |
|---|---|---|
| Price | $1.48 | $2.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $10.60 |
| AVG Volume (30 Days) | 482.1K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $67,887,000.00 | ★ $70,000,000.00 |
| Revenue This Year | $21.84 | N/A |
| Revenue Next Year | $11.96 | N/A |
| P/E Ratio | ★ N/A | $6.93 |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $1.37 | $1.20 |
| 52 Week High | $3.50 | $4.94 |
| Indicator | VLN | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 29.41 |
| Support Level | $1.66 | $2.61 |
| Resistance Level | $1.75 | $2.84 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 1.79 | 22.59 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.